Experimental vaccine aims to fight Virus-Linked cancers
NCT ID NCT07525024
Summary
This study is testing a new vaccine called KSD-101 in people with blood cancers linked to the Epstein-Barr virus (EBV). The vaccine is made from special immune cells and is designed to teach the body's immune system to attack the cancer. Researchers will observe 80 patients who have either not responded to standard treatments or who choose this vaccine to try to prevent their cancer from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV ASSOCIATED LYMPHOID NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin-Hainan Hospital，Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)
Qionghai, Hainan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.